What is Selank?
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analogue of tuftsin, a naturally occurring tetrapeptide produced by the spleen that plays a role in immune function and mood regulation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank has been approved in Russia as both an anxiolytic and nootropic medication.
It is often compared to Semax (another Russian peptide nootropic) and is characterized by its anxiolytic-without-sedation profile — a distinct advantage over traditional benzodiazepines.
How Selank Works
The mechanism of Selank is multifaceted and not fully elucidated:
- GABA system modulation: Influences GABA-A receptor function similarly to benzodiazepines but without causing dependence or sedation
- BDNF upregulation: Increases brain-derived neurotrophic factor, supporting neuroplasticity and learning
- Serotonin and dopamine: Modulates monoamine neurotransmitter systems involved in mood
- Enkephalinase inhibition: Inhibits enzymes that break down endogenous enkephalins (natural opioid peptides), enhancing their anxiolytic effects
- Immune modulation: Like its parent compound tuftsin, Selank has immunomodulatory properties
Key Research Findings
Anxiety
Multiple Russian clinical studies demonstrate Selank’s efficacy for:
- Generalized anxiety disorder
- Neurasthenia
- Performance anxiety and stress
Crucially, it reduces anxiety without the sedation, cognitive impairment, or addiction potential of benzodiazepines.
Cognitive Effects
Selank has shown nootropic properties including:
- Improved working memory and attention
- Faster information processing
- Enhanced learning in animal models
- Possible benefit in ADHD symptoms
Mood and Depression
Some evidence suggests Selank reduces depressive symptoms, possibly through BDNF upregulation and monoamine modulation.
Administration
In Russian clinical practice, Selank is administered as a nasal spray (intranasal route), which allows direct delivery to the brain bypassing the blood-brain barrier. It can also be administered subcutaneously in research settings.
Side Effects
Selank has a notably benign side effect profile:
- No sedation
- No withdrawal or dependence
- Occasional mild headache
- Transient nasal irritation (intranasal route)
Medical Disclaimer: Selank is not FDA-approved in the United States. Its legal status varies internationally. This content is for educational purposes only. Do not use Selank without consulting a qualified healthcare provider.
Related Reading
- Selank and Semax: Nootropic Peptides from Russian Research — Full review of both peptides’ anxiolytic, cognitive, and neuroprotective evidence
- Peptide Pipeline: Clinical Trials to Watch in 2026 — Selank Phase 2 European trial (GAD/MCI) as the first EMA-standard data
- Peptide Drug Interactions and Safety Guide — Interaction considerations with anxiolytics and other CNS medications
- Peptide Safety: What to Know Before Starting — Safety framework for gray-market peptides
Safety Profile Summary
Well-documented safety in Russian clinical use. Non-addictive, no withdrawal syndrome, no sedation. Limited large-scale Western clinical trial data.
References & Further Reading
- 1. Inozemtseva LS, et al. Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus in Vivo. Dokl Biol Sci. 2008;421:241-3. [PubMed ↗]
- 2. Zozulya AA, et al. The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bull Exp Biol Med. 2001;131(4):315-7. [PubMed ↗]
- 3. Zozulia AA, et al. Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. [PubMed ↗]
- 4. Uchakina ON, et al. Immunomodulatory Effects of Selank in Patients with Anxiety-Asthenic Disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-5. [PubMed ↗]